Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant SARS-CoV-2 S protein (B.1.617), trimer, His Tag (MALS verified), 50µg  

Recombinant SARS-CoV-2 S protein (B.1.617), trimer, His Tag (MALS verified), 50µg

Recombinant SARS-CoV-2 Spike (T95I, G142D, E154K, L452R, E484Q, D614G, P681R, Q1071H), AA Val 16 - Pro 1213, expressed from human 293 cells (HEK293), trimer, His Tag (MALS verified)

Synonyms: Recombinant, protein, S protein, Spike glycoprotein, S glycoprotein, COVID-19

More details

SPN-C52Hr-50

Availability: within 7 days

540,00 €

Background
It's been reported that Coronavirus  can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Source
Recombinant SARS-CoV-2 Spike Trimer, His Tag (SPN-C52Hr) is expressed from human 293 cells (HEK293). It contains AA Val 16 - Pro 1213 (Accession # QHD43416.1). The mutations (T95I, G142D, E154K, L452R, E484Q, D614G, P681R) were identified in the SARS-CoV-2 variants which emerged in India (known as B.1.617). Proline substitutions (F817P, A892P, A899P, A942P, K986P, V987P) and alanine substitutions (R683A and R685A) are introduced to stabilize the trimeric prefusion state of SARS-CoV-2 S protein and abolish the furin cleavage site, respectively.
Predicted N-terminus: Val 16

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 138.2 kDa. The protein migrates as 150-200 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for reconstitution instructions and specific concentrations.

Bioactivity
Please refer to product data sheet.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Clinical and Translational Updates

(1) "Decline of antibody titres three months after two doses of BNT162b2 in non-immunocompromised adults"
Erice, Varillas-Delgado, Caballero
Clin Microbiol Infect (2021)
(2) "SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis"
Bensouna, Caudwell, Kubab et al
Am J Kidney Dis (2021)
(3) "Dynamics prediction of emerging notable spike protein mutations in SARS-CoV-2 implies a need for updated vaccines"
Al-Zyoud, Haddad
Biochimie (2021)
Showing 1-3 of 16712 papers.
Please refer to product data sheet.